Harpoon Therapeutics: HPN217 Receives FDA Fast Track Designation
2/3 14:12
(RTTNews) - Harpoon Therapeutics, Inc. (HARP) said FDA has granted Fast Track designation to HPN217, a BCMA-targeting TriTAC, for the treatment of patients with relapsed, refractory multiple myeloma who have received at least four lines of therapy....